Chemomab Therapeutics (CMMB) EBIT (2017 - 2025)
Chemomab Therapeutics posted quarterly EBIT of -$16.2 million for Q4 2025, up 35.58% year-on-year from -$12.0 million in Q4 2024, and down 979.5% on a QoQ basis from $1.8 million in Q3 2025.
Chemomab Therapeutics (CMMB) has 8 years of EBIT data on file, last reported at -$16.2 million in Q4 2025.
- For the quarter ending Q4 2025, EBIT rose 35.58% year-over-year to -$16.2 million; the trailing twelve-month figure through Dec 2025 stood at -$35.8 million (down 162.55% YoY), and the FY2025 full-year result was -$9.6 million, up 35.09% from the prior year.
- EBIT for Q4 2025 stood at -$16.2 million, down from $1.8 million in the prior quarter.
- Across five years, EBIT topped out at $9.0 million in Q1 2023 and bottomed at -$25.2 million in Q4 2024.
- The 5-year median for EBIT is $3.7 million (2024), against an average of $186529.4.
- The widest annual swing landed in 2022, when EBIT soared 364.25%; it then tumbled 943.17% in 2024.
- A 5-year view of EBIT shows it stood at -$5.0 million in 2021, then soared by 256.51% to $7.9 million in 2022, then slumped by 62.12% to $3.0 million in 2023, then sank by 943.17% to -$25.2 million in 2024, then surged by 35.58% to -$16.2 million in 2025.
- The last three EBIT figures came in at -$16.2 million (Q4 2025), $1.8 million (Q3 2025), and -$25.2 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | -16.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16.22 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Dec 31, 2024 | -25.18 Mn |
| Sep 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | 3.77 Mn |
| Mar 31, 2024 | 4.05 Mn |
| Dec 31, 2023 | 2.99 Mn |
| Sep 30, 2023 | 3.91 Mn |
| Jun 30, 2023 | 8.20 Mn |
| Mar 31, 2023 | 9.05 Mn |
| Dec 31, 2022 | 7.88 Mn |
| Sep 30, 2022 | 7.84 Mn |
| Jun 30, 2022 | 7.21 Mn |
| Mar 31, 2022 | -5.10 Mn |
| Dec 31, 2021 | -5.04 Mn |
| Sep 30, 2021 | -2.97 Mn |
| Jun 30, 2021 | -2.77 Mn |
| Dec 31, 2019 | -9.21 Mn |
| Sep 30, 2019 | 3.90 Mn |
| Jun 30, 2019 | 4.44 Mn |
| Mar 31, 2019 | 5.43 Mn |
| Dec 31, 2018 | 2.98 Mn |
| Sep 30, 2018 | 2.51 Mn |
| Jun 30, 2018 | 4.16 Mn |
| Mar 31, 2018 | 3.40 Mn |
| Dec 31, 2017 | 1.88 Mn |